Malnutrition risk as a predictor of quality of life and skeletal muscle depletion following upper gastrointestinal cancer diagnosis: A longitudinal analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
105 participants (43% oesophageal, 20% gastric, 37% pancreatic cancer), older age predicted low SMI and low SMD.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
As a modifiable factor, addressing malnutrition risk could improve HROQL and preserve muscle in upper gastrointestinal cancer. [TRIAL REGISTRATION] Australian New Zealand Clinical Trials Registry, 27 January 2017 (12617000152325).
[OBJECTIVES] Low skeletal muscle index (SMI) and radiodensity (SMD) are established prognostic indicators in cancer.
APA
Hanna L, Nguo K, et al. (2025). Malnutrition risk as a predictor of quality of life and skeletal muscle depletion following upper gastrointestinal cancer diagnosis: A longitudinal analysis.. The journal of nutrition, health & aging, 29(9), 100623. https://doi.org/10.1016/j.jnha.2025.100623
MLA
Hanna L, et al.. "Malnutrition risk as a predictor of quality of life and skeletal muscle depletion following upper gastrointestinal cancer diagnosis: A longitudinal analysis.." The journal of nutrition, health & aging, vol. 29, no. 9, 2025, pp. 100623.
PMID
40602077 ↗
Abstract 한글 요약
[OBJECTIVES] Low skeletal muscle index (SMI) and radiodensity (SMD) are established prognostic indicators in cancer. This study investigated risk factors for low and decreasing SMI and low SMD in upper gastrointestinal cancer and examined the influence of malnutrition risk on the association between SMI and health-related quality of life (HRQOL).
[DESIGN] Longitudinal analysis of randomised controlled trial outcome data.
[SETTING] Three health services in Victoria, Australia.
[PARTICIPANTS] Adults newly diagnosed with oesophageal, gastric or pancreatic cancer.
[MEASUREMENTS] Outcomes assessed at diagnosis, and three- and six-month follow-up. SMI and SMD were assessed via computed tomography imaging analysis, with low values determined using established sex-specific thresholds. Malnutrition risk was assessed using the Patient Generated Subjective Global Assessment (Short Form), and HRQOL with the EORTC QLQ-C30. Multiple logistic regression identified risk factors for low SMI and low SMD at baseline, and SMI decline (≥5%) from baseline to 3 months. Associations between SMI and HRQOL were examined using multiple linear regression, adjusting for malnutrition risk.
[RESULTS] Among 105 participants (43% oesophageal, 20% gastric, 37% pancreatic cancer), older age predicted low SMI and low SMD. Low SMI risk was higher in females and lower with higher BMI. At three months, 57% (37/65) experienced ≥5% SMI loss, associated with higher malnutrition risk, higher baseline SMI, and post-diagnosis weight loss. Malnutrition risk was a strong independent predictor of poorer HRQOL score at all timepoints. Lower or decreasing SMI (≥5%) was also independently associated with poorer HRQOL on some scales.
[CONCLUSION] Malnutrition risk independently predicted lower HRQOL and muscle loss, and may confound the relationship between SMI and HRQOL. As a modifiable factor, addressing malnutrition risk could improve HROQL and preserve muscle in upper gastrointestinal cancer.
[TRIAL REGISTRATION] Australian New Zealand Clinical Trials Registry, 27 January 2017 (12617000152325).
[DESIGN] Longitudinal analysis of randomised controlled trial outcome data.
[SETTING] Three health services in Victoria, Australia.
[PARTICIPANTS] Adults newly diagnosed with oesophageal, gastric or pancreatic cancer.
[MEASUREMENTS] Outcomes assessed at diagnosis, and three- and six-month follow-up. SMI and SMD were assessed via computed tomography imaging analysis, with low values determined using established sex-specific thresholds. Malnutrition risk was assessed using the Patient Generated Subjective Global Assessment (Short Form), and HRQOL with the EORTC QLQ-C30. Multiple logistic regression identified risk factors for low SMI and low SMD at baseline, and SMI decline (≥5%) from baseline to 3 months. Associations between SMI and HRQOL were examined using multiple linear regression, adjusting for malnutrition risk.
[RESULTS] Among 105 participants (43% oesophageal, 20% gastric, 37% pancreatic cancer), older age predicted low SMI and low SMD. Low SMI risk was higher in females and lower with higher BMI. At three months, 57% (37/65) experienced ≥5% SMI loss, associated with higher malnutrition risk, higher baseline SMI, and post-diagnosis weight loss. Malnutrition risk was a strong independent predictor of poorer HRQOL score at all timepoints. Lower or decreasing SMI (≥5%) was also independently associated with poorer HRQOL on some scales.
[CONCLUSION] Malnutrition risk independently predicted lower HRQOL and muscle loss, and may confound the relationship between SMI and HRQOL. As a modifiable factor, addressing malnutrition risk could improve HROQL and preserve muscle in upper gastrointestinal cancer.
[TRIAL REGISTRATION] Australian New Zealand Clinical Trials Registry, 27 January 2017 (12617000152325).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Aged
- Female
- Humans
- Male
- Middle Aged
- Esophageal Neoplasms
- Gastrointestinal Neoplasms
- Longitudinal Studies
- Malnutrition
- Muscle
- Skeletal
- Pancreatic Neoplasms
- Quality of Life
- Risk Factors
- Sarcopenia
- Stomach Neoplasms
- Tomography
- X-Ray Computed
- Victoria
- EORTC QLQ-C30
- Health-related quality of life
- Low muscle mass
- PG-SGA
- Skeletal muscle index
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.